Acne Drugs Global Market Report 2024

The acne drugs market size has grown steadily in recent years. It will grow from $5.84 billion in 2023 to $6.11 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%. The growth observed in the historical period can be ascribed to several factors, including the escalating prevalence of acne, a growing population, robust economic expansion, an upswing in pharmaceutical spending, increased disposable income, and a rise in healthcare expenditure.

The acne drugs market size is expected to see steady growth in the next few years. It will grow to $7.3 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The anticipated growth in the forecast period can be linked to accelerated economic expansion, heightened healthcare expenditure, the substantial potential of emerging economies, a rising teenage population, and the prevalence of sedentary lifestyles. Noteworthy trends expected in the forecast period involve strategic investments in narrow-spectrum antibiotics, the formulation of combination therapies for acne treatment, financial commitments in cannabis products, particularly those containing cannabis oil, partnerships for the development of novel drugs, and leveraging social media platforms for the marketing of acne treatment products.

The acne drug market is significantly influenced by the rise in people's disposable income, serving as a major driving force. The escalation in disposable income typically mirrors an improved economy, resulting in augmented wages and salaries, consequently amplifying healthcare spending. According to the Bureau of Economic Analysis, disposable personal income surged by $7.3 billion in July 2023. This upsurge in disposable income, coupled with amplified expenditure on facial care products, is anticipated to persist, thereby fueling market growth during the forecast period.

The escalating prevalence of acne is projected to be a key driver propelling the growth of the acne drug market in the foreseeable future. Acne, a skin condition arising from clogged pores due to oil and dead skin cells, prompts individuals to seek remedies. Acne drugs function by mitigating inflammation, reducing oil production, and preventing pore blockage, ultimately enhancing the appearance of acne-prone skin. With nearly 90% of the global population affected by some form of acne, the condition poses a widespread challenge. In the United States alone, approximately 12 million individuals struggle with severe acne, which, if untreated, can result in skin scarring. Consequently, a significant portion of the population invests in acne care drugs and products to manage the condition. Hence, the mounting prevalence of acne stands as a substantial driver catalyzing growth within the acne drug market.

The latest trend shaping the acne drug market is the adoption of combination therapy, involving the simultaneous use of two drugs with distinct mechanisms of action. Such combinations exhibit enhanced efficacy and improved adherence compared to monotherapy, which involves using a single drug in isolation. This approach combines a topical retinoid drug, effective in unclogging pores, with an antimicrobial drug utilized for treating infections in acne management. Examples of combination therapy include products such as Epiduo, Acanya, Ziana, and Benzamycin, manufactured by Galderma, Allergan, Medicis, and Atrix, respectively.

Leading companies operating in the acne drug market are actively engaged in developing advanced receptor inhibitor drugs and broadening their research into treatment advancements to gain a competitive edge in the burgeoning healthcare sector. Advanced receptor inhibitor drugs function by blocking the activity of specific receptors within the body. For instance, in September 2023, Sun Pharmaceutical Industries Ltd., an India-based biopharmaceutical company, introduced (PR)WINLEVI (clascoterone cream 1% w/w). WINLEVI is formulated to mitigate the effects of acne hormones on the skin by disrupting the androgen cascade, departing from the topical approach in acne treatment that targets follicular hyperkeratinization, inflammation reduction, or antibacterial properties. While the precise mechanism of action of WINLEVI remains under study, it aims to suppress androgen receptor activities within sebaceous gland cells, thereby reducing sebum (oil) production and inflammatory cytokines associated with acne.

In December 2021, the pharmaceutical and healthcare giant Sanofi S.A., headquartered in France and renowned for its expertise in drug development and commercialization, successfully acquired Origimm Biotechnology GmbH for an undisclosed sum. This strategic move by Sanofi aims to bolster its vaccine research and development (R&D) pipeline, enhance its proficiency in skin microbiome and skin immunology, and broaden its array of treatment options for acne. Furthermore, as a result of this acquisition, Sanofi is poised to extend the reach of these innovative products to encompass the entire European market. Origimm Biotechnology GmbH, based in Austria, is a pioneering pharmaceutical company known for its advancements in identifying pathogenic components of the skin microbiome and bacterial antigens responsible for skin diseases.

Major companies operating in the acne drugs market report are Johnson & Johnson, Galderma S.A., Almirall SA, Bausch Health Companies Inc., GlaxoSmithKline, Reckitt Benckiser Group, Mayne Pharma Group Limited, Allergan Plc., Cipher Pharmaceuticals, Sol Gel Advanced Topical Therapy, Pfizer Inc., Novartis AG, Merck & Co. Inc., Amgen Inc., Abbott, AstraZeneca, Eli Lilly and Company, Daiichi Sankyo Company Limited, Sinopharm Group Co. Ltd., Mylan N.V., F. Hoffmann-La Roche Ltd., Bayer AG, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., Allergan, Cipla Inc., Zydus Cadila, Otsuka Pharmaceutical Co. Ltd., Shanghai Pharmaceuticals Holding Co. Ltd., Jiangsu Hengrui Medicine, Guangzhou Baiyunshan Pharmaceutical, China Meheco Co Ltd., Huadong Medicine Co. Ltd., Pfizer Inc., Galderma S.A., Amgen Europe B.V., Roche Holding AG, Ranbaxy Laboratories, Stiefel Laboratories, BIOCAD, Zentiva (Sanofi), Gedeon Richter PLC, Polpharma SA Pharmaceutical Works, Egis Group, Dermira Inc., Bausch Health Companies Inc., Estee Lauder Inc., Nimue Skincare International.

North America was the largest region in the acne drugs market in 2023. The Middle East is expected to be the largest growing region in the global acne drugs market during the forecast period. The regions covered in the acne drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acne drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary categories of acne drugs include inflammatory and non-inflammatory variants. Inflammatory acne drugs are employed for the treatment of mild to moderate inflammatory acne. Key therapeutic classes comprise retinoids, antibiotics, salicylic acid, and benzoyl peroxide. These medications find application across various end-user segments, including hospitals, clinics, pharmacies, drug stores, and ambulatory surgical centers.

The acne drugs market research report is one of a series of new reports that provides acne drugs market statistics, including acne drugs industry global market size, regional shares, competitors with an acne drugs market share, detailed acne drugs market segments, market trends and opportunities, and any further data you may need to thrive in the acne drugs industry. This acne drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acne drugs market consists of sales of retinoids, antibiotics, and diapsone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.